3-D Matrix Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
3-D Matrix has been growing earnings at an average annual rate of 18.2%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 44.3% per year.
Wichtige Informationen
18.2%
Wachstumsrate der Gewinne
36.7%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 31.9% |
| Wachstumsrate der Einnahmen | 44.3% |
| Eigenkapitalrendite | -99.3% |
| Netto-Marge | -20.0% |
| Nächste Ertragsaktualisierung | 12 Dec 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
We Think 3-D Matrix (TSE:7777) Has A Fair Chunk Of Debt
Sep 10
3-D Matrix, Ltd. (TSE:7777) Doing What It Can To Lift Shares
Jun 08Investors Continue Waiting On Sidelines For 3-D Matrix, Ltd. (TSE:7777)
Feb 263-D Matrix (TYO:7777) Is Carrying A Fair Bit Of Debt
Apr 223-D Matrix's (TYO:7777) Shareholders Are Down 68% On Their Shares
Feb 23Aufschlüsselung der Einnahmen und Ausgaben
Wie 3-D Matrix Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Jul 24 | 5,246 | -1,050 | 4,817 | 557 |
| 30 Apr 24 | 4,588 | -255 | 4,647 | 555 |
| 31 Jan 24 | 3,740 | -1,062 | 4,319 | 514 |
| 31 Oct 23 | 3,166 | -2,204 | 4,175 | 508 |
| 31 Jul 23 | 2,718 | -1,913 | 4,198 | 449 |
| 30 Apr 23 | 2,314 | -2,445 | 3,995 | 451 |
| 31 Jan 23 | 2,064 | -1,906 | 3,714 | 468 |
| 31 Oct 22 | 1,850 | -1,032 | 3,452 | 543 |
| 31 Jul 22 | 1,589 | -1,621 | 2,978 | 638 |
| 30 Apr 22 | 1,506 | -1,894 | 2,713 | 684 |
| 31 Jan 22 | 1,319 | -2,516 | 2,527 | 756 |
| 31 Oct 21 | 1,192 | -2,167 | 2,465 | 775 |
| 31 Jul 21 | 1,155 | -2,401 | 2,312 | 763 |
| 30 Apr 21 | 1,024 | -2,012 | 2,168 | 785 |
| 31 Jan 21 | 871 | -2,524 | 1,951 | 755 |
| 31 Oct 20 | 828 | -2,708 | 1,836 | 770 |
| 31 Jul 20 | 740 | -2,666 | 1,800 | 827 |
| 30 Apr 20 | 672 | -3,096 | 1,846 | 801 |
| 31 Jan 20 | 641 | -2,796 | 1,842 | 806 |
| 31 Oct 19 | 524 | -2,799 | 1,731 | 780 |
| 31 Jul 19 | 417 | -2,767 | 1,610 | 771 |
| 30 Apr 19 | 328 | -2,554 | 1,497 | 786 |
| 31 Jan 19 | 254 | -2,481 | 1,419 | 748 |
| 31 Oct 18 | 243 | -2,320 | 1,446 | 712 |
| 31 Jul 18 | 214 | -2,136 | 1,434 | 645 |
| 30 Apr 18 | 228 | -1,866 | 1,363 | 562 |
| 31 Jan 18 | 713 | -1,410 | 1,392 | 552 |
| 31 Oct 17 | 689 | -1,244 | 1,373 | 512 |
| 31 Jul 17 | 673 | -1,199 | 1,316 | 463 |
| 30 Apr 17 | 615 | -1,392 | 1,285 | 469 |
| 31 Jan 17 | 138 | -1,798 | 1,192 | 481 |
| 31 Oct 16 | 120 | -2,453 | 1,092 | 534 |
| 31 Jul 16 | 103 | -2,555 | 1,107 | 615 |
| 30 Apr 16 | 141 | -2,459 | 1,181 | 661 |
| 31 Jan 16 | 171 | -2,331 | 1,164 | 697 |
| 31 Oct 15 | 151 | -1,776 | 1,233 | 736 |
| 31 Jul 15 | 145 | -1,812 | 1,242 | 841 |
| 30 Apr 15 | 99 | -1,994 | 1,185 | 816 |
| 31 Jan 15 | 51 | -2,054 | 1,189 | 773 |
| 31 Oct 14 | 58 | -1,972 | 1,092 | 737 |
| 31 Jul 14 | 60 | -1,819 | 1,028 | 593 |
| 30 Apr 14 | 107 | -1,525 | 953 | 598 |
| 31 Jan 14 | 88 | -1,339 | 806 | 550 |
Qualität der Erträge: 7777 is currently unprofitable.
Wachsende Gewinnspanne: 7777 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 7777 is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.
Beschleunigtes Wachstum: Unable to compare 7777's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: 7777 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 7777 has a negative Return on Equity (-99.34%), as it is currently unprofitable.